Cass Review

Last updated

Logo of the Cass Review Cass-review-logo.svg
Logo of the Cass Review

The Independent Review of Gender Identity Services for Children and Young People (commonly, the Cass Review) was commissioned in 2020 by NHS England and NHS Improvement [1] and led by Hilary Cass, a retired consultant paediatrician and the former president of the Royal College of Paediatrics and Child Health. [2] It dealt with gender services for children and young people, including those with gender dysphoria and those identifying as transgender.

Contents

The final report was published on 10 April 2024, [3] and was endorsed by both the Conservative and Labour parties. The review led to a UK ban on prescribing puberty blockers to those under 18 (with the exception of existing patients or those in a clinical trial). [4] The Gender Identity Development Service (GIDS) at the Tavistock and Portman NHS Foundation Trust closed in March 2024 and replaced in April with two new services, which are intended to be the first of eight regional centres. [5] In August, the pathway by which patients are referred to gender clinics was revised and a review of adult services commissioned. [6] A clinical trial into puberty blockers is planned for early 2025. [7]

The review has been criticised by several transgender-related medical organisations, and a number of international medical organisations have expressed disagreement with some of its conclusions. [8] [9] [10] [11]

Background

The interim report [12] of the Cass Review was published in March 2022. It said that the rise in referrals had led to the staff being overwhelmed, and recommended the creation of a network of regional hubs to provide care and support to young people. The report said that the clinical approach used by the Gender Identity Development Service (GIDS) "has not been subjected to some of the usual control measures" [13] typically applied with new treatments, and raised concerns about the lack of data collection by GIDS. [14] [15] While GIDS initially followed the Dutch protocol, the interim review said there were "significant differences" in the current NHS approach. [16] Children with comorbidities did not receive adequate psychological support, endocrinologists administering puberty blockers did not attend multidisciplinary meetings nor did the frequency of meetings increase when adolescents received puberty blockers, all of which the Dutch Approach recommends. [16]

The interim report further said that GPs and other non-GIDS staff felt "under pressure to adopt an unquestioning affirmative approach" [17] to children unsure of their gender, "overshadowing" other issues such as poor mental health. The Tavistock and Portman NHS Foundation Trust said "being respectful of someone's identity does not preclude exploration", and "We agree that support should be holistic, based on the best available evidence and that no assumptions should be made about the right outcome for any given young person." [18]

The final report of the Cass Review was published on 10 April 2024. It included several systematic reviews of scientific literature carried out by University of York, encompassing the patient cohort, service pathways, international guidelines, social transitioning, puberty blockers and hormone treatments. [19]

Methodology

The Cass Review commissioned several independent, peer-reviewed systematic reviews into different areas of healthcare for children and young people with gender identity issues, including gender dysphoria. [20] [21] The reviews were carried out by academics at the University of York's Centre for Reviews and Dissemination, one of three bodies funded by the National Institute for Health and Care Research (NIHR) to provide a systematic review service to the NHS. [22] The topics covered by the systematic reviews were: [19]

In the systematic reviews the report commissioned, tools such as the Mixed Methods Appraisal Tool and modified versions of the Newcastle–Ottawa scale were used to assess the quality of the studies available [31] [32] because no blind control studies - those usually thought of as having the highest quality - were available. [33] The systematic reviews performed meta-analyses to ascertain the best evidence-based knowledge on their respective subjects to inform the report's findings and recommendations. [34] [35]

In its collection of evidence, the report also carried out qualitative and quantitative research into young people with gender dysphoria and their health outcomes, [36] carried out listening sessions and focus groups with service users and parents, held meetings with advocacy groups, and gathered existing documented insights into the lived experiences of patients. [37]

Findings

Lack of research

The report states on page 20 that, "When the Review started, the evidence base, particularly in relation to the use of puberty blockers and masculinising / feminising hormones, had already been shown to be weak"; and that after the examination of over 100 pieces of potential evidence, that "there continues to be a lack of high-quality evidence in this area". [38]

Increase in referrals

Cass Review Figure 11: Child and Adolescent Referrals for Gender Dysphoria (UK, GIDS) Cass-review-figure-11.png
Cass Review Figure 11: Child and Adolescent Referrals for Gender Dysphoria (UK, GIDS)

The report found no clear explanation for the rise in the number of children and adolescents with gender dysphoria, but said there was broad agreement for attribution to a mix of biological and psychosocial factors. Suggested influences included a lower threshold for medical treatment, social media-related mental health consequences, abuse, access to information regarding gender dysphoria, struggles with emerging sexual orientation, and early exposure to online pornography. The report considered a rise in acceptance of transgender identities to be insufficient to explain the increase. [39] [23] [40] [41]

Social transition

A systematic review evaluated 11 studies assessing the outcomes of social transition in minors using a modified version of the Newcastle-Ottawa scale and considered 9 to be low quality and two to be moderate quality. [31] [24] The report said that insufficient evidence was available to assess whether social transition in childhood has positive or negative effects on mental health, and that there was weak evidence for efficacy in adolescence. It also said that sex of rearing seems to influence gender identity, and hypothesised that early social transition may change the way a child's gender identity develops. [42]

The report classified social transition as an "active intervention". It also advised caution in approaching social transition, and stressed the need for clinical involvement in determining risks and benefits, saying that it is not a role that can be undertaken without appropriate clinical training. [41] [43]

Puberty blockers

The report said that the evidence base and rationale for early puberty suppression remains unclear, with unknown effects on cognitive and psychosexual development. A systematic review [26] examined 50 studies on the use of puberty blockers using a modified version of the Newcastle–Ottawa scale and considered only one to be of high quality, along with a further 25 being of moderate quality, and the remaining 24 being of low quality. The review concluded that the lack of evidence means no conclusions can be made regarding the impact on gender dysphoria and mental health, but did find evidence of bone health being compromised during treatment. The review disagreed with the idea of puberty blockers providing youth patients with "time to think", due to the finding that nearly all patients who went on blockers later decided to proceed on to hormone therapy. [44] [26] [45] [41] [46] [47] For birth-registered males the report states uncontroversially that blockers taken too early can make a later vaginoplasty more difficult due to insufficient penile growth, although blockers do prevent lower voice and facial hair. [48]

Hormone therapy

The report said that many unknowns remained for the use of hormone treatment among under-18s, despite longstanding use among transgender adults, with poor long-term follow-up data and outcome information on those starting younger. A systematic review [27] evaluated 53 studies on transgender hormone therapy using a modified version of the Newcastle-Ottawa scale, and considered only one study to be of high quality, 33 moderate and 19 low quality. Overall, the review found some evidence that hormone treatment improves psychological outcomes after 12 months, but found insufficient/inconsistent evidence regarding physical risks and benefits. The review advised that there should be a 'clear clinical rationale' for the prescription of hormone therapy under 18 years of age. [44] [27] [45] [43]

Psychosocial intervention

A systematic review assessed ten studies on the efficacy of psychosocial support interventions in transgender minors using the Mixed Methods Appraisal Tool and considered only one to be of medium quality, with the remaining nine being of low quality. The review concluded that no robust conclusions can be made and more research is needed. [25] [49] The report said that the evidence for psychosocial intervention as opposed to hormonal was "as weak as research on endocrine treatment", but that the result of psychological treatment was "either benefit or no change". [50] [51]

Clinical pathways

Cass Review Figure 34: Outline of medical pathway at start of Review Cass-review-figure-34.png
Cass Review Figure 34: Outline of medical pathway at start of Review

The report said that clinicians cannot be certain which children and young people will have an enduring trans identity in adulthood, and that for most, a medical pathway will not be the most appropriate. When a medical pathway is clinically indicated, wider mental health or psychosocial issues should also be addressed. Due to a lack of follow-up, the number of individuals who detransitioned after hormone treatment was unknown. [44]

The Cass Review attempted to work with the Gender Identity Development Service and the NHS adult gender services to "fill some of the gaps in follow-up data for the approximately 9,000 young people who have been through GIDS to develop a stronger evidence base." However, despite encouragement from NHS England, "the necessary cooperation was not forthcoming." [52] [53]

International guidelines

Cass Review Table 6: Critical appraisal domain scores Cass-review-table-6.png
Cass Review Table 6: Critical appraisal domain scores

A systematic review [29] [30] assessed 23 regional, national and international guidelines covering key areas of practice, such as care principles, assessment methods and medical interventions. Most guidelines were said to lack editorial independence and developmental rigour, and were nearly all influenced by the 2009 Endocrine Society guideline and the 2012 WPATH guideline, which were themselves closely linked. The Cass review questioned the guidelines' reliability, and concluded that no single international guideline regarding transgender care could be applied in its entirety to NHS England. [44]

Conflicting clinical views

The report identified conflicting views among clinicians regarding appropriate treatment, with expectations of care sometimes deviating from clinical norms. It said that disputes over language such as "exploratory" and "affirmative" approaches meant it was difficult to establish neutral terminology. Some clinicians feared working with gender-questioning young people. [54] The report said that some professionals were concerned about being accused of conversion practices, and were likewise concerned about legislation to ban conversion therapy. The report went on to say that many professionals were "overshadowed by an unhelpfully polarised debate around conversion practices". [55] [56]

Recommendations

The report made 32 recommendations covering areas including assessment of children and young people, diagnosis, psychological interventions, social transition, improving the evidence base underpinning medical and non-medical interventions, puberty blockers and hormone treatments, service improvements, education and training, clinical pathways, detransition and private provision. [57]

Recommendations included:

Implementation

NHS England responded positively to the interim and final reports. As of April 2024 they have implemented a number of measures. [5] The Gender Identity Development Service (GIDS) at the Tavistock and Portman NHS Foundation Trust closed in March 2024. [5] Two new services, located in the north west of England and in London, opened in April 2024, which are intended to be the first of up to eight regional services. [5] These will follow a new service specification for the "assessment, diagnosis and treatment of children and young people presenting with gender incongruence". [5] Puberty suppressing hormones are no longer routinely available in NHS youth gender services. [5] New patients that have been assessed as possibly benefiting from them will be required to participate in a clinical trial that is being set up by the National Institute for Health and Care Research. [20] [74] A new board, chaired by Simon Wessely will encourage further research in the areas highlighted in the review as having a weak evidence base. [5]

In May 2024, then Health Secretary Victoria Atkins implemented an emergency ban on the prescription of puberty blockers by medical providers of such by patients outside of the NHS. The ban permits the use by under-18s with gender dysphoria who were already taking them, or within a clinical trial. In July 2024, the ban was challenged in the High Court by campaign group TransActual and the Good Law Project. [75] This challenge was dismissed by the court. The Health Secretary, Wes Streeting welcomed the "evidence led" decision and said efforts were being made to set up a clinical trial. [4] [76]

On August 7th 2024, NHS England announced a status update, [77] including the publication of a new pathway specification [78] for young people being considered for referral to specialist gender services. One recommendation is that those considering social transition be seen quickly by a clinical professional with relevant experience.

The clinical trial to study the "potential benefits and harms of puberty suppressing hormones for children and young people" was due to start late 2024 but is now delayed to early 2025. [7]

Regarding Adult Care

The Cass Review did not cover Adult Care. so in May 2024 Cass wrote to NHS England, to pass on the feedback regards Adult Care from clinicians who had approached her during the Review process. Clinicians across the country in adult gender services had expressed concern about both the clinical practice and model of care. Some clinicians in other settings, especially general practice, had raised concerns about the treatment of patients under their care. [79]

On 7th August NHS England included a response to the Adult Care letter, in a status report for the Under 18 services. [80]

NHS England on 8th August announced there would be a review of adult services led by Dr. David Levy, medical director for Lancashire and South Cumbria integrated care board, to assess "the quality (i.e. effectiveness, safety, and patient experience) and stability of each service, but also whether the existing service model is still appropriate for the patients it is caring for". [6] [81] [82]

Reception

Interim report in February 2022

The interim report, published in February 2022, said that there were "gaps in the evidence" over the use of puberty blockers. A public consultation was held and a further review of evidence by NICE said there was "not enough evidence to support the safety or clinical effectiveness of puberty suppressing hormones to make the treatment routinely available at this time." As a result, NHS England stopped prescribing them to children. [83] [84] [85]

In April 2022, Health Secretary Sajid Javid told MPs that services in this area were too affirmative and narrow, and "bordering on ideological". [86]

In November 2022, the World Professional Association for Transgender Health (WPATH), along with ASIAPATH, EPATH, PATHA, and USPATH issued a statement criticising the NHS England interim service specifications based on the interim report. It contested several points in the report, including the pathologizing of gender diversity, the making of "outdated" assumptions regarding the nature of transgender individuals, "ignoring" newer evidence regarding such matters, and making calls for an "unconscionable degree of medical and state intrusion" into everyday matters such as pronouns and clothing choice, as well as into access to gender-affirming care. It further said that "the denial of gender-affirming treatment under the guise of 'exploratory therapy' is tantamount to 'conversion' or 'reparative' therapy under another name". [8]

Final report in April 2024

Reception among UK political parties

Prime Minister at the time Rishi Sunak said that the findings "shine a spotlight" on the need for a cautious approach to child and adolescent gender care. [87] [88] Wes Streeting, the shadow Health Secretary, welcomed the final report, saying that the report "must provide a watershed moment for the NHS's gender identity services" and committing the Labour Party to implementing the report's recommendations in full. [89] [90] [91] Speaking to Sky News, Shadow Home Secretary Yvette Cooper said that Labour welcomed the Cass Review and committed to implementing all of its recommendations. [92]

The Scottish Government said it would "take the time to consider the findings". [93] [94] SNP politician Joanna Cherry called for an overhaul to services in Scotland for gender-questioning children, including screening out neurodivergent patients, and an end to the use of puberty blockers. [94] Humza Yousaf, First Minister of Scotland and SNP leader at the time of the final report's release, said that while the Scottish government would discuss the Cass Review with health authorities, it would leave its implementation up to clinicians. [95] In July 2024 a multi-disciplinary team commissioned by the Chief Medical Officer to assess the recommendations of the Cass Review advised the Scottish Government to pause puberty blockers pending further research. [96] [97]

Response from NHS England and NHS Scotland

In response to the report, the NHS England National Director of Specialised Commissioning John Stewart sent a letter to Cass stating that it would review the use of gender-affirming transgender hormone therapy in adults in a similar manner as was done for puberty blockers in the Cass Review. [98] [99] [100]

On 18 April 2024, NHS Scotland announced that it had paused prescribing puberty blockers to children referred by its specialist gender clinic. [101]

Response from other health bodies in the United Kingdom

The British Psychological Society said they support "the report's primary focus of expanding service capacity across the country" and acknowledged that "while psychological therapies will continue to have an incredibly important role to play in the new services, more needs to be done to assess the effectiveness of these psychological interventions." BPS president Roman Raczka commended the review as "thorough and sensitive", in light of the complex and controversial nature of the subject. He said "it will take time to carefully review and respond to the whole report" but he was sure the field of psychology would learn lessons from it. He welcomed the recommendation for a consortium of relevant bodies to develop better trainings and upskill the workforce. [102]

The Royal College of Psychiatrists welcomed the report and strongly agreed with some of its recommendations. They supported the emphasis on a holistic and person-centred approach and research to improve the evidence basis for treatment protocols. They said that some of its trans members, and the wider trans community, had concerns about availability of treatments while awaiting research, said there was "a strong view that the report makes assumptions in areas such as social transition and possible explanations for the increase in the numbers of people who have a trans or gender diverse identity, which contrasts with the more decisive statements about treatment approaches", and called for direct and comprehensive involvement of those with lived experience. [103]

The Royal College of Paediatrics and Child Health said they would take the time to review the recommendations in full and said that data collected had identified a lack of confidence by paediatricians and GPs to support this patient group, which the RCPCH pledged to address by developing new training. RCPCH President's Steve Turner thanked Cass and her team for the "massive undertaking" and said they would consider the report's recommendations. [104]

In response to the Cass Review, the Royal College of General Practitioners updated its position statement on the role of the GP in transgender care. They advise that, for patients under 18, no GP should prescribe puberty blockers outside of a clinical trial, and the prescription of gender-affirming hormones should be left to specialists. The GCGP affirms it will fully implement the recommendations of the Cass Review. They specifically highlight recommendations for services 17–25 year-olds, noting that some other fields are moving to a 0–25 service for better continuity of care, and the need for additional services for those people considering detransition. [105]

British Medical Association

On 31 July 2024 the British Medical Association, which is both a trade union and professional body, [106] publicly called for a pause on the review's implementation while it conducted an evaluation that it intends to complete by January 2025. [107] The BMA's council voted in favor of a motion to "publicly critique the Cass Review" due to "unsubstantiated recommendations driven by unexplained study protocol deviations, ambiguous eligibility criteria, and exclusion of trans-affirming evidence". The BMA criticised the related ban on puberty blockers, arguing this wasn't a decision for politicians to make, while calling for more research. [108] [107]

In response a spokesperson for the Cass Review said it had consulted widely, including "those with lived experience, health staff and leading experts in the field" and that the research base was large and comprehensive, gathering evidence from 237 papers from 18 countries, and the Department of Health and Social Care said that it did not support a delay and that NHS England would implement Cass' recommendations. [109] Likewise, [110] the Academy of Medical Royal Colleges's response said its focus would be on implementing the Cass Review, providing treatment that is holistic and evidence based. It was critical of what it called "further speculative work" that risked further polarisation, and warned against "members of the medical profession questioning the validity of the evidence and consequently the findings of the independent Cass review". [111]

The Royal College of Paediatrics and Child Health acknowledged there had been some academic criticism of the Cass Review and a call to pause the implementation of recommendations. They regarded this as a "backwards step", further delaying care that already has "unacceptable waiting times". While remaining mindful of "emerging criticisms of any chosen approach", their priority is "that this group of children receive timely, holistic and high-quality care." [112]

In August 2024, about 1000 doctors [113] signed an open letter calling on the BMA to abandon its plan to "publicly critique" the Cass Review, which they call a "pointless exercise". The doctors criticise the BMA Council for not consulting with the membership and question how a fair critique is possible, given the Council's already stated opposition. The signatories, the majority of whom are BMA members, include 57 professors and 22 former or current presidents of royal medical colleges. [114] [115]

Response from other health bodies globally

The American Academy of Pediatrics and the Endocrine Society both responded to the report by reaffirming their support for gender-affirming care for minors and saying that their current policies supporting such treatments are "grounded in evidence and science". [116]

The Canadian Pediatric Society responded to the report by saying "Current evidence shows puberty blockers to be safe when used appropriately, and they remain an option to be considered within a wider view of the patient's mental and psychosocial health." [117]

The Amsterdam University Medical Center put out a statement saying that while it agrees with the goals of reducing wait times and improving research, it disagrees that the research-base for puberty blockers is insufficient, asserting that puberty blockers have been used in trans care for decades. [118]

The Royal Australian and New Zealand College of Psychiatrists rejected calls for an inquiry into trans healthcare following the release of the Cass Review. [119] They characterised the Cass Review as one review among several in the field. [119] They emphasised that, "assessment and treatment should be patient centred, evidence-informed and responsive to and supportive of the child or young person's needs and that psychiatrists have a responsibility to counter stigma and discrimination directed towards trans and gender diverse people." [119]

Response from transgender specialist medical bodies

The World Professional Association for Transgender Health released an email statement saying that the report "is rooted in the false premise that non-medical alternatives to care will result in less adolescent distress" and further criticised recommendations which "severely restrict access to physical healthcare, and focus almost exclusively on mental healthcare for a population which the World Health Organization does not regard as inherently mentally ill". [120] [121] An official statement expanded on these concerns, criticising Cass's "negligible prior knowledge or clinical experience", asserting that "the (research and consensus-based) evidence is such to recommend that providing medical treatment including puberty-blocking medication and hormone therapy is helpful and often life-saving", and questioning the provision of puberty blockers only in the context of a research protocol: "The use of a randomized blinded control group, which would lead to the highest quality of evidence, is ethically not feasible." [122] [ dead link ]

The Professional Association for Transgender Health Aotearoa (PATHA), a New Zealand professional organisation, said that the Cass Review made "harmful recommendations" and was not in line with international consensus, and that "Restricting access to social transition is restricting gender expression, a natural part of human diversity." They further said that several people involved in the review "previously advocated for bans on gender-affirming care in the United States, and have promoted non-affirming 'gender exploratory therapy', which is considered a conversion practice." [10] [123] A joint statement by Equality Australia signed by the Australian Professional Association for Trans Health (AusPATH) and PATHA among others said the review "downplays the risk of denying treatment to young people with gender dysphoria and limits their options by placing restrictions on their access to care". [124] [10] [125]

Assorted responses

Amnesty International criticised "sensationalised coverage" of the review, stating "This review is being weaponised by people who revel in spreading disinformation and myths about healthcare for trans young people." [126] [127] Trans youth charity Mermaids and the LGBTQIA+ charity Stonewall endorsed some of the report's recommendations, such as expanding service provisions with the new regional hubs, but raised concerns the review's recommendations may lead to barriers for transgender youth in accessing care. [123]

Gender-critical organisations including Sex Matters and Genspect welcomed the report. Stella O'Malley of Genspect expressed concern that if a conversion therapy ban were to criminalise any exploration into why a child identifies as trans, it "would ban the very therapy that Cass is saying should be prioritised". [128]

The British Equality and Human Rights Commission described it as a "vital milestone" and called for all service providers to fully implement the recommendations of the review. [129] The report was praised by some academics in the UK, who agreed with its findings stating a lack of evidence; [90] [52] [130] while others both in the UK [131] and internationally [117] [132] [133] disagreed with the report's methodology and findings. It was praised by author J.K. Rowling and United Nations Special Rapporteur Reem Alsalem. [134] [135] [136] [137]

The Integrity Project at Yale Law School released a white paper critiquing the Cass Review, accusing it of having "serious flaws." [138] [139] [140] The white paper, co-authored by a group of eight legal scholars and medical researchers, argues that the Cass Review "levies unsupported assertions about gender identity, gender dysphoria, standard practices, and safety of gender-affirming medical treatments, and it repeats claims that have been disproved by sound evidence" and that "is not an authoritative guideline or standard of care, nor is it an accurate restatement of the available medical evidence on the treatment of gender dysphoria." [138] [139]

Hilary Cass's response

In the week after the release of the final report, Cass described receiving abusive emails and was given security advice to avoid public transport. [141] She also said that "disinformation" had frequently been spread online about the report. Cass said "if you deliberately try to undermine a report that has looked at the evidence of children's healthcare, then that's unforgivable. You are putting children at risk by doing that." [141] There were widespread false claims from critics of the report that it had dismissed 98% of the studies it collected and all studies which were not double-blind experiments. Cass described these claims as being "completely incorrect". Although only 2% of the papers collected were considered to be of high quality, 60% of the papers, including those considered to be of moderate quality, were considered in the report's evidence synthesis. [35] [142] [143] She criticised Labour MP Dawn Butler for repeating, during a debate in the House of Commons, incorrect claims that the review had dismissed more than 100 studies. [144] [145] [146] After talking with Cass, Butler subsequently used a point of order to admit her mistake and correct the record in Parliament, stating the figure came from a briefing she had received from Stonewall. [143] [147] [148] [149]

In an interview with The New York Times in May 2024, Cass expressed concern that her review was being weaponized to suggest that trans people do not exist, saying "that's really disappointing to me that that happens, because that's absolutely not what we're saying." She also clarified that her review was not about defining what trans means or rolling back health care, stating "There are young people who absolutely benefit from a medical pathway, and we need to make sure that those young people have access — under a research protocol, because we need to improve the research — but not assume that that's the right pathway for everyone." [150]

In an interview with WBUR-FM in May 2024, Cass responded to WPATH's criticism about prioritising non-medical care, saying the review did not take a position about which is best. Cass hoped that "every young person who walks through the door should be included in some kind of proper research protocol" and for those "where there is a clear, clinical view" that the medical pathway is best will still receive that, and be followed up to eliminate the "black hole of not knowing what's best". On the allegation that the review was predicated on the belief that a trans outcome for a child was the worst outcome, Cass emphasised that a medical pathway, with lifetime implications and treatment, required caution but "it's really important to say that a cis outcome and a trans outcome have equal value". [151]

See also

Related Research Articles

Gender dysphoria (GD) is the distress a person experiences due to a mismatch between their gender identity—their personal sense of their own gender—and their sex assigned at birth. The term replaced the previous diagnostic label of gender identity disorder (GID) in 2013 with the release of the diagnostic manual DSM-5. The condition was renamed to remove the stigma associated with the term disorder.

The Standards of Care for the Health of Transgender and Gender Diverse People (SOC) is an international clinical protocol by the World Professional Association for Transgender Health (WPATH) outlining the recommended assessment and treatment for transgender and gender-diverse individuals across the lifespan including social, hormonal, or surgical transition. It often influences clinicians' decisions regarding patients' treatment. While other standards, protocols, and guidelines exist – especially outside the United States – the WPATH SOC is the most widespread protocol used by professionals working with transgender or gender-variant people.

<span class="mw-page-title-main">Gender transition</span> Changing gender presentation to accord with gender identity

Gender transition is the process of affirming and expressing one's internal sense of gender, as opposed to the gender assigned to them at birth. There are two major facets of gender transitioning: a social transition, and a medical transition; almost all transgender people will socially transition, and most will undergo some degree of medical transition.

Pediatric endocrinology is a medical subspecialty dealing with disorders of the endocrine glands, such as variations of physical growth and sexual development in childhood, diabetes and many more.

Gender dysphoria in children (GD), also known as gender incongruence of childhood, is a formal diagnosis for children who experience significant discontent due to a mismatch between their assigned sex and gender identity. The diagnostic label gender identity disorder in children (GIDC) was used by the Diagnostic and Statistical Manual of Mental Disorders (DSM) until it was renamed gender dysphoria in children in 2013 with the release of the DSM-5. The diagnosis was renamed to remove the stigma associated with the term disorder.

<span class="mw-page-title-main">Transgender youth</span> Children and adolescents who are transgender

Transgender youth are children or adolescents who do not identify with the sex they were assigned at birth. Because transgender youth are usually dependent on their parents for care, shelter, financial support, and other needs, they face different challenges compared to adults. According to the World Professional Association for Transgender Health, the American Psychological Association, and the American Academy of Pediatrics, appropriate care for transgender youth may include supportive mental health care, social transition, and/or puberty blockers, which delay puberty and the development of secondary sex characteristics to allow children more time to explore their gender identity.

Puberty blockers are medicines used to postpone puberty in children. The most commonly used puberty blockers are gonadotropin-releasing hormone (GnRH) agonists, which suppress the natural production of sex hormones, such as androgens and estrogens. Puberty blockers are used to delay the development of unwanted secondary sex characteristics in transgender children, so as to allow transgender youth more time to explore their gender identity. The same drugs are also used to treat other conditions, such as precocious puberty in young children and some hormone-sensitive cancers in adults.

Transgender hormone therapy, also called hormone replacement therapy (HRT) or gender-affirming hormone therapy (GAHT), is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is masculinization or feminization:

Transgender health care includes the prevention, diagnosis and treatment of physical and mental health conditions for transgender individuals. A major component of transgender health care is gender-affirming care, the medical aspect of gender transition. Questions implicated in transgender health care include gender variance, sex reassignment therapy, health risks, and access to healthcare for trans people in different countries around the world. Gender affirming health care can include psychological, medical, physical, and social behavioral care. The purpose of gender affirming care is to help a transgender individual conform to their desired gender identity.

<span class="mw-page-title-main">Transgender rights in the United Kingdom</span>

Transgender rights in the United Kingdom have varied significantly over time, with transgender Britons facing many issues not experienced by non-trans individuals. These include various laws and public attitudes in regards to identity documents, as well as anti-discrimination measures used by or pertaining to transgender people, in the areas of employment, education, housing and social services, amongst others.

<span class="mw-page-title-main">Mermaids (charity)</span> British charity that supports transgender youth

Mermaids is a British charity and advocacy organisation that supports gender variant and transgender youth. It also provides inclusion and diversity training. Mermaids was founded in 1995 by a group of parents of gender nonconforming children and became a charitable incorporated organisation in 2015.

The Gender Identity Development Service (GIDS) was a nationally operated health clinic in the United Kingdom that specialised in working with children with gender identity issues, including gender dysphoria. The service closed on 28 March 2024 after serious concerns were repeatedly raised over a number of years by several independent NHS whistleblowers.

<i>Bell v Tavistock</i> 2021 UK case regarding puberty blockers

Bell v Tavistock was a case before the Court of Appeal on the question of whether puberty blockers could be prescribed to under-16s with gender dysphoria. The Court of Appeal said that "it was for clinicians rather than the court to decide on competence" to consent to receive puberty blockers.

<span class="mw-page-title-main">Arkansas House Bill 1570 (2021)</span> 2021 Arkansas state law

Arkansas House Bill 1570, also known as the Save Adolescents From Experimentation (SAFE) Act or Act 626, is a 2021 law in the state of Arkansas that bans gender-affirming medical procedures for transgender people under 18, including puberty blockers, hormone therapy, and sex reassignment surgery. The law also bans the use of public funds for and prohibits insurance from covering gender transition procedures, while doctors who provide treatment in violation of the ban can be sued for damages or professionally sanctioned. The measure makes Arkansas the first U.S. state to make gender-affirming medical care illegal.

Stella O'Malley is an Irish psychotherapist and author, with three books on parenting and mental health. She is a regular contributor to Irish national newspapers, podcasts, and TV. She made a documentary about gender dysphoria in children for Channel 4, and is the founder of Genspect, a self-described gender critical organisation opposed to gender affirming care.

<span class="mw-page-title-main">Genspect</span> Organization opposing transgender rights

Genspect is an international group founded in June 2021 by psychotherapist Stella O'Malley that has been described as gender-critical. Genspect opposes gender-affirming care, as well as social and medical transition for transgender people. Genspect opposes allowing transgender people under 25 years old to transition, and opposes laws that would ban conversion therapy on the basis of gender identity. Genspect also endorses the unproven concept of rapid-onset gender dysphoria (ROGD), which proposes a subclass of gender dysphoria caused by peer influence and social contagion. ROGD has been rejected by major medical organisations due to its lack of evidence and likelihood to cause harm by stigmatizing gender-affirming care.

<span class="mw-page-title-main">Society for Evidence-Based Gender Medicine</span> Organization opposing transgender rights

The Society For Evidence-Based Gender Medicine (SEGM) is a non-profit organization that is known for its opposition to gender-affirming care for transgender youth and for engaging in political lobbying. The group routinely cites the unproven concept of rapid-onset gender dysphoria and has falsely claimed that conversion therapy techniques are only practiced on the basis of sexual orientation rather than gender identity. SEGM is often cited in anti-transgender legislation and court cases, sometimes filing court briefs. It is not recognized as a scientific organization by the international medical community.

Laura Edwards-Leeper is an American psychologist and founder of the first pediatric gender clinic of the United States. She also served as head of the Child and Adolescent Committee for the World Professional Association for Transgender Health.

GenderGP is an online gender clinic founded in 2015 by English physicians Helen Webberley and Mike Webberley. It is based in Singapore but provides services worldwide. It has been the subject of controversy within the United Kingdom as a result of regulatory actions taken against its founders.

The Jeff Younger custody battle is a highly contentious and nationally publicized family law dispute in the US, between parents Anne Georgulas (Petitioner) and Jeff Younger (Respondent) regarding their twin boys, born in May 2012. Litigated between 2018-2023 in the Texas Courts, and 2023-present in the Los Angeles Superior Court, the case attracts national attention. Georgulas seeks to commence with puberty blockers, cross-sex hormones, and bottom surgery, contending one of the boys suffers from the psychological condition of gender dysphoria, and further claims that the boy is a transgender girl. Younger disputes that the boy has gender dysphoria. Moreover, Younger and his expert witness Miriam Grossman contend that, even assuming the boy does have gender dysphoria, gender affirming care has not been proven safe or effective under the standards of evidence-based medicine.

References

  1. ↑ "NHS commissioning » Independent review into gender identity services for children and young people". NHS England (Primary source). Archived from the original on 9 April 2024. Retrieved 9 April 2024.
  2. ↑ "The Chair – Cass Review". Cass Independent Review (Primary source). Archived from the original on 9 April 2024. Retrieved 9 April 2024.
  3. ↑ Josh Parry; Hugh Pym (10 April 2024). "Hilary Cass: Weak evidence letting down children over gender care". BBC News (News). Archived from the original on 27 April 2024. Retrieved 28 April 2024.
  4. 1 2 "Puberty blockers ban is lawful, says High Court". BBC News. 29 July 2024. Archived from the original on 1 August 2024. Retrieved 30 July 2024.
  5. 1 2 3 4 5 6 7 "NHS commissioning » Implementing advice from the Cass Review". www.england.nhs.uk. Archived from the original on 4 June 2023. Retrieved 28 April 2024.
  6. 1 2 "NHS England » NHS England update on work to transform gender identity services". www.england.nhs.uk. Retrieved 8 August 2024.
  7. 1 2 Campbell, Denis (7 August 2024). "Delayed puberty blocker clinical trial to start next year in England". The Guardian. Retrieved 8 August 2024.
  8. 1 2 "WPATH, ASIAPATH, EPATH, PATHA, and USPATH Response to NHS England in the United Kingdom (UK): Statement regarding the Interim Service Specification for the Specialist Service for Children and Young People with Gender Dysphoria (Phase 1 Providers) by NHS England" (PDF) (Press release). 25 November 2022. Archived (PDF) from the original on 14 April 2024. Retrieved 13 April 2024.
  9. ↑ WPATH; EPATH (10 October 2023). "30.10.23 EPATH - WPATH Joint NHS Statement Final" (PDF). WPATH (Press release). Archived from the original on 11 April 2024. Retrieved 14 April 2024.
  10. 1 2 3 "Cass Review out of step with high-quality care provided in Aotearoa". PATHA – Professional Association for Transgender Health Aotearoa (Press release). 11 April 2024. Archived from the original on 11 April 2024. Retrieved 11 April 2024.
  11. ↑ "Cass Review' author: More 'caution' advised for gender-affirming care for youth". WBUR-FM . 8 May 2024. Archived from the original on 9 May 2024. Retrieved 9 May 2024.
  12. ↑ Cass review interim report 2022.
  13. ↑ Cass review interim report 2022, p. 15.
  14. ↑ Brooks, Libby (10 March 2022). "NHS gender identity service for children can't cope with demand, review finds 10 March 2022". The Guardian . Archived from the original on 13 March 2022. Retrieved 13 March 2022.
  15. ↑ Bannerman, Lucy (10 March 2022). "Tavistock gender clinic not safe for children, report finds". The Times . Archived from the original on 29 March 2022. Retrieved 29 March 2022.
  16. 1 2 Cass review interim report 2022, p. 18.
  17. ↑ Cass review interim report 2022, p. 17.
  18. ↑ Crawford, Angus (23 April 2022). "Sajid Javid to review gender treatment for children" (News). BBC News. Archived from the original on 24 April 2022. Retrieved 24 April 2022.
  19. 1 2 "Gender Identity Service Series". Archives of Disease in Childhood (Series of reviews commissioned to inform the Cass Review). Archived from the original on 10 April 2024. Retrieved 10 April 2024.
  20. 1 2 Thornton, Jacqui (April 2024). "Cass Review calls for reformed gender identity services". The Lancet (News). 403 (10436): 1529. doi:10.1016/S0140-6736(24)00808-0. PMID   38643770. Cass commissioned four systematic reviews of the evidence on key issues...
  21. 1 2 Cass review final report 2024, p. 28.
  22. ↑ Cass review final report 2024, p. 56.
  23. 1 2 Taylor, Jo; Hall, Ruth; Langton, Trilby; Fraser, Lorna; Hewitt, Catherine Elizabeth (9 April 2024). "Characteristics of children and adolescents referred to specialist gender services: a systematic review". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326681. ISSN   0003-9888. PMID   38594046. Archived from the original on 10 April 2024. Retrieved 11 April 2024.
  24. 1 2 Hall, Ruth; Mitchell, Alex; Taylor, Jo; Heathcote, Claire; Langton, Trilby; Fraser, Lorna; Hewitt, Catherine Elizabeth (9 April 2024). "Impact of social transition in relation to gender for children and adolescents: a systematic review". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326112. PMID   38594055. Archived from the original on 22 April 2024. Retrieved 22 April 2024.
  25. 1 2 Heathcote, Claire; Mitchell, Alex; Taylor, Jo; Hall, Ruth; Langton, Trilby; Fraser, Lorna; Hewitt, Catherine Elizabeth; Jarvis, Stuart William (9 April 2024). "Psychosocial support interventions for children and adolescents experiencing gender dysphoria or incongruence: a systematic review". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326347. PMID   38594045. Archived from the original on 23 April 2024. Retrieved 23 April 2024.
  26. 1 2 3 Taylor, Jo; Mitchell, Alex; Hall, Ruth; Heathcote, Claire; Langton, Trilby; Fraser, Lorna; Hewitt, Catherine Elizabeth (9 April 2024). "Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326669. ISSN   0003-9888. PMID   38594047. Archived from the original on 10 April 2024. Retrieved 11 April 2024.
  27. 1 2 3 Taylor, Jo; Mitchell, Alex; Hall, Ruth; Langton, Trilby; Fraser, Lorna; Hewitt, Catherine Elizabeth (9 April 2024). "Masculinising and feminising hormone interventions for adolescents experiencing gender dysphoria or incongruence: a systematic review". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326670. ISSN   0003-9888. PMID   38594053. Archived from the original on 10 April 2024. Retrieved 11 April 2024.
  28. ↑ Taylor, Jo; Hall, Ruth; Langton, Trilby; Fraser, Lorna; Hewitt, Catherine Elizabeth (9 April 2024). "Care pathways of children and adolescents referred to specialist gender services: a systematic review". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326760. PMID   38594052. Archived from the original on 28 April 2024. Retrieved 28 April 2024.
  29. 1 2 Taylor, J; Hall, R; Heathcote, C; Hewitt, CE; Langton, T; Fraser, L (9 April 2024). "Clinical guidelines for children and adolescents experiencing gender dysphoria or incongruence: a systematic review of guideline quality (part 1)". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326499. PMID   38594049. Archived from the original on 2 August 2024. Retrieved 13 April 2024.
  30. 1 2 Taylor, J; Hall, R; Heathcote, C; Hewitt, CE; Langton, T; Fraser, L (9 April 2024). "Clinical guidelines for children and adolescents experiencing gender dysphoria or incongruence: a systematic review of recommendations (part 2)". Archives of Disease in Childhood (Review). doi:10.1136/archdischild-2023-326500. PMID   38594048. Archived from the original on 29 June 2024. Retrieved 13 April 2024.
  31. 1 2 Cass review final report 2024, p. 161.
  32. ↑ Cass review final report 2024, pp. 2, 3, Appendix 2.
  33. ↑ James, Beal (26 April 2024). "Cass author condemns 'misinformation' spread by trans lawyer". The Times (News). Archived from the original on 22 April 2024. Retrieved 26 April 2024. During a systematic review, researchers looking at studies on transgender healthcare found no blind control ones — so used another system altogether to determine study quality.
  34. ↑ Cass review final report 2024, p. 4.
  35. 1 2 Mackintosh, Thomas (20 April 2024). "Cass Review: Gender care report author attacks 'misinformation'". BBC News (News). Archived from the original on 21 April 2024. Retrieved 23 April 2024.
  36. ↑ Cass review final report 2024, pp. 52–53.
  37. ↑ Cass review final report 2024, p. 60.
  38. ↑ Cass review final report 2024, p. 20.
  39. ↑ Cass review final report 2024, pp. 114–121.
  40. ↑ Martin, Daniel (8 April 2024). "Children must not be rushed to change gender, report warns". The Telegraph. Archived from the original on 13 April 2024. Retrieved 14 April 2024.
  41. 1 2 3 Bannerman, Lucy; Beal, James; Hayward, Eleanor; Koronka, Poppy (10 April 2024). "Nine key findings from the Cass review into gender transition". The Times. Archived from the original on 14 April 2024. Retrieved 14 April 2024.
  42. ↑ Cass review final report 2024, p. 164.
  43. 1 2 Thomas, Rebecca (10 April 2024). "Children failed by NHS amid toxic debate on gender identity, major review finds". The Independent. Archived from the original on 10 April 2024. Retrieved 14 April 2024.
  44. 1 2 3 4 Cass review final report 2024.
  45. 1 2 Gregory, Andrew; Davis, Nicola; Sample, Ian (10 April 2024). "Gender medicine 'built on shaky foundations', Cass review finds". The Guardian. Archived from the original on 2 August 2024. Retrieved 15 April 2024.
  46. ↑ Parry, Josh; Pym, Hugh (9 April 2024). "Hilary Cass: Weak evidence letting down children over gender care". BBC News . Archived from the original on 9 April 2024. Retrieved 17 April 2024.
  47. ↑ Lawless, Jill (10 April 2024). "A major UK report says trans children are being let down by toxic debate and lack of evidence". Associated Press . Archived from the original on 12 April 2024. Retrieved 26 April 2024.
  48. ↑ Cass review final report 2024, p. 178.
  49. ↑ Cass review final report 2024, p. 153.
  50. ↑ Cass review final report 2024, p. 196.
  51. ↑ Cass review final report 2024, p. 5.
  52. 1 2 Abbasi, Kamran (11 April 2024). "The Cass review: an opportunity to unite behind evidence informed care in gender medicine". BMJ. 385: q837. doi:10.1136/bmj.q837. ISSN   1756-1833. Archived from the original on 11 April 2024. Retrieved 11 April 2024.
  53. ↑ Cass review final report 2024, pp. 190–191.
  54. ↑ Cass review final report 2024, p. 20, 202.
  55. ↑ Cass review final report 2024, p. 150.
  56. ↑ Adu, Aletha; Gentleman, Amelia (11 April 2024). "Hilary Cass warns Kemi Badenoch over risks of conversion practices ban". The Guardian. Archived from the original on 3 July 2024. Retrieved 14 April 2024.
  57. ↑ Cass review final report 2024, pp. 28–45.
  58. ↑ Cass review final report 2024, pp. 210, 224–225.
  59. ↑ Newton, Storm (10 April 2024). "Cass Review: What are the recommendations on child gender care?". The Independent. Archived from the original on 23 April 2024. Retrieved 27 April 2024.
  60. ↑ Cass review final report 2024, pp. 30, 31.
  61. ↑ Cass review final report 2024, p. 29.
  62. ↑ Cass review final report 2024, p. 32.
  63. ↑ Cass review final report 2024, p. 34.
  64. 1 2 3 4 5 Cass review final report 2024, p. 35.
  65. ↑ Cass review final report 2024, p. 37.
  66. ↑ Cass review final report 2024, p. 38.
  67. 1 2 3 Cass review final report 2024, p. 39.
  68. 1 2 Cass review final report 2024, p. 42.
  69. ↑ Cass review final report 2024, p. 40.
  70. 1 2 Cass review final report 2024, p. 41.
  71. ↑ Cass review final report 2024, p. 43.
  72. 1 2 Cass review final report 2024, p. 44.
  73. ↑ Cass review final report 2024, p. 45.
  74. ↑ "Final report – FAQs – Cass Review". cass.independent-review.uk. Archived from the original on 28 April 2024. Retrieved 28 April 2024.
  75. ↑ Vinter, Robyn (6 June 2024). "Campaigners mount legal challenge against puberty blockers ban in Britain". The Guardian. ISSN   0261-3077 . Retrieved 13 August 2024.
  76. ↑ Siddique, Haroon; correspondent, Haroon Siddique Legal affairs (29 July 2024). "Puberty blockers ban imposed by Tory government is lawful, high court rules". The Guardian. ISSN   0261-3077. Archived from the original on 2 August 2024. Retrieved 30 July 2024.
  77. ↑ "NHS England » Referral pathway for specialist service for children and young people with gender incongruence". www.england.nhs.uk. Archived from the original on 8 August 2024. Retrieved 11 August 2024.
  78. ↑ "NHS England » Referral pathway for specialist service for children and young people with gender incongruence". www.england.nhs.uk. Archived from the original on 8 August 2024. Retrieved 11 August 2024.
  79. ↑ Cass, Helen (16 May 2024). "INDEPENDENT REVIEW OF GENDER IDENTITY SERVICES FOR CHILDREN AND YOUNG PEOPLE – ADULT GENDER DYSPHORIA CLINICS" (PDF). NHS England. Archived (PDF) from the original on 10 August 2024. Retrieved 11 August 2024.
  80. ↑ "NHS England » NHS England update on work to transform gender identity services". www.england.nhs.uk. Archived from the original on 8 August 2024. Retrieved 11 August 2024.
  81. ↑ "Review into safety of adult gender services to begin within weeks". The Independent. 7 August 2024. Archived from the original on 11 August 2024. Retrieved 11 August 2024.
  82. ↑ Fox, Aine (7 August 2024). "Review into safety of adult gender services to begin within weeks". Evening Standard. Archived from the original on 11 August 2024. Retrieved 11 August 2024.
  83. ↑ Campbell, Denis (12 March 2024). "Children to stop getting puberty blockers at gender identity clinics, says NHS England". The Guardian (News). Archived from the original on 12 March 2024. Retrieved 26 April 2024.
  84. ↑ Parry, Josh (12 March 2024). "NHS England to stop prescribing puberty blockers". BBC News (News). Archived from the original on 13 March 2024. Retrieved 26 April 2024.
  85. ↑ Ghorayshi, Azeen (9 April 2024). "Youth Gender Medications Limited in England, Part of Big Shift in Europe" . The New York Times (News). Archived from the original on 21 April 2024. Retrieved 26 April 2024.
  86. ↑ "Sajid Javid to review gender treatment for children". BBC News (News). 23 April 2022. Archived from the original on 9 May 2024. Retrieved 9 May 2024.
  87. ↑ "PM urges 'extreme caution' on gender treatments – as major review finds NHS failed children". Sky News (News). Archived from the original on 14 April 2024. Retrieved 15 April 2024.
  88. ↑ "Cass review: Health secretary criticises gender care 'culture of secrecy'". BBC News (News). 11 April 2024. Archived from the original on 11 April 2024. Retrieved 17 April 2024.
  89. ↑ Crerar, Pippa (12 April 2024). "Cass review must be used as 'watershed moment' for NHS gender services, says Streeting". The Guardian (News). ISSN   0261-3077. Archived from the original on 3 July 2024. Retrieved 15 April 2024.
  90. 1 2 Campbell, Denis; Gentleman, Amelia; Vinter, Robyn (10 April 2024). "Thousands of children unsure of gender identity 'let down by NHS', report finds". The Guardian (News). Archived from the original on 3 July 2024. Retrieved 10 April 2024.
  91. ↑ Paul, Mark (10 April 2024). "British Labour says it will implement Cass findings on care for trans children if it wins election". The Irish Times (News). Archived from the original on 15 April 2024. Retrieved 16 April 2024.
  92. ↑ "'How could we be giving kids puberty blockers for 20 years?' – Labour on Cass report". Sky News (News). 10 April 2024. Archived from the original on 10 April 2024. Retrieved 10 April 2024.
  93. ↑ Paton, Craig (10 April 2024). "Scottish Government pledges to consider findings of Cass Review into gender". The Independent (News). Archived from the original on 17 April 2024. Retrieved 17 April 2024.
  94. 1 2 Miller, Dale; Fox, Aine (11 April 2024). "SNP MP Joanna Cherry calls for puberty blockers to be banned in Scotland in wake of Cass Review on gender". The Scotsman (News). Archived from the original on 11 April 2024. Retrieved 15 April 2024.
  95. ↑ Brooks, Libby (16 April 2024). "No case for closing Scotland's only NHS gender service clinic, says first minister". The Guardian (News). Archived from the original on 3 July 2024. Retrieved 16 April 2024.
  96. ↑ "Scottish government advised to halt puberty blockers". BBC News (News). 5 July 2024. Archived from the original on 5 July 2024. Retrieved 5 July 2024.
  97. ↑ "Improving gender identity healthcare". Scottish Government (gov.scot) (Press release). 5 July 2024. Retrieved 5 July 2024.
  98. ↑ Campbell, Denis; Gentleman, Amelia (10 April 2024). "Adult transgender clinics in England face inquiry into patient care". The Guardian (News). Archived from the original on 10 April 2024. Retrieved 17 April 2024.
  99. ↑ "NHS England's Response to the Final Report of the Independent Review of Gender Identity Services for Children and Young People". NHS England (Letter). 6 August 2024 [10 April 2024]. Archived from the original on 10 April 2024. Retrieved 15 April 2024.
  100. ↑ Searles, Michael; Donnelly, Laura; Martin, Daniel (9 April 2024). "NHS to review all transgender treatment". The Telegraph (News). Archived from the original on 15 April 2024. Retrieved 16 April 2024.
  101. ↑ "Scotland's under-18s gender clinic pauses puberty blockers". BBC (News). Archived from the original on 3 July 2024. Retrieved 19 April 2024.
  102. ↑ Stewart, John; Palmer, James (10 April 2024). "BPS responds to final Cass Review report". The British Psychological Society (Press release). Archived from the original on 3 July 2024. Retrieved 13 April 2024.
  103. ↑ Smith, Lade (22 April 2024). "Detailed response to The Cass Review's Final Report" (Press release). Royal College of Psychiatrists. Archived from the original on 16 May 2024. Retrieved 18 May 2024.
  104. ↑ "RCPCH responds to publication of the final report from the Cass Review" (Press release). Royal College of Paediatrics and Child Health. 10 April 2024. Archived from the original on 21 May 2024. Retrieved 18 May 2024.
  105. ↑ "The role of the GP in transgender care" (Position statement). Royal College of General Practitioners. Archived from the original on 29 July 2024. Retrieved 2 August 2024.
  106. ↑ "BMA as a professional association and trade union". British Medical Association. Retrieved 14 August 2024.
  107. 1 2 "BMA to undertake an evaluation of the Cass Review on gender identity services for children and young people" (Press release). British Medical Association. 31 July 2024. Archived from the original on 31 July 2024. Retrieved 31 July 2024.
  108. ↑ Fox, Aine (31 July 2024). "Doctors' union will 'critique' Cass Review after criticising puberty blocker ban". The Independent (News). Archived from the original on 31 July 2024. Retrieved 31 July 2024.
  109. ↑ "BMA calls for ban on puberty blockers to be lifted". BBC News (News). 1 August 2024. Archived from the original on 1 August 2024. Retrieved 1 August 2024.
  110. ↑ Feinmann, Jane (2 August 2024). "Puberty blockers: BMA calls for lifting of ban on prescribing to children". BMJ (News). 386: q1722. doi:10.1136/bmj.q1722. ISSN   1756-1833. PMID   39095076. Archived from the original on 2 August 2024. Retrieved 2 August 2024.
  111. ↑ "Academy statement: Implementation of the Cass Review". Academy of Medical Royal Colleges (Press release). Archived from the original on 2 August 2024. Retrieved 2 August 2024.
  112. ↑ "Calls to evaluate the Cass Review - RCPCH response". RCPCH. 5 August 2024. Archived from the original on 24 May 2024. Retrieved 8 August 2024.
  113. ↑ "Doctors question union over puberty blocker statement". BBC News (News). 9 August 2024. Archived from the original on 10 August 2024. Retrieved 10 August 2024.
  114. ↑ Feinmann, Jane (8 August 2024). "Nearly 900 doctors sign letter urging BMA to abandon inquiry into Cass review". BMJ (News). 386: q1772. doi:10.1136/bmj.q1772. ISSN   1756-1833. Archived from the original on 8 August 2024. Retrieved 8 August 2024.
  115. ↑ Barnes, Hannah (8 August 2024). "Hundreds of doctors are challenging the BMA's stance on puberty blockers". New Statesman (News). Archived from the original on 8 August 2024. Retrieved 8 August 2024.
  116. ↑ "Cass Review' author: More 'caution' advised for gender-affirming care for youth". WBUR-FM (News). 8 May 2024. Archived from the original on 9 May 2024. Retrieved 9 May 2024.
  117. 1 2 Johnson, Lisa (15 April 2024). "What Canadian doctors say about new U.K. review questioning puberty blockers for transgender youth". CBC (News). Archived from the original on 16 April 2024. Retrieved 17 April 2024.
  118. ↑ "Een reactie van Amsterdam UMC op de Cass review over transgenderzorg" (Press release). Amsterdam UMC. 18 April 2024. Archived from the original on 3 July 2024. Retrieved 19 April 2024.
  119. 1 2 3 Moore, Elizabeth (29 May 2024). "A letter from members regarding the Cass Review and the College's response". The Royal Australian and New Zealand College of Psychiatrists (Letter and reply). Archived from the original on 3 July 2024. Retrieved 19 June 2024.
  120. ↑ Fiore, Kristina (16 April 2024). "Cass Review Finds Weak Evidence for Puberty Blockers, Hormones in Youth Gender Care". MedPage Today (News). Archived from the original on 27 April 2024. Retrieved 27 April 2024.
  121. ↑ Riedel, Samantha (12 April 2024). "Advocates Say a Controversial U.K. Report on Healthcare for Trans Kids Is "Fundamentally Flawed"". Them (News). Archived from the original on 14 April 2024. Retrieved 13 April 2024.
  122. ↑ "WPATH AND USPATH COMMENT ON THE CASS REVIEW" (PDF) (Press release). WPATH and USPATH. Archived (PDF) from the original on 18 May 2024. Retrieved 18 May 2024.
  123. 1 2 "How LGBTQIA+ charities are responding to the Cass review". Gay Times (News). 11 April 2024. Archived from the original on 11 April 2024. Retrieved 11 April 2024.
  124. ↑ "Cass Review out-of-line with medical consensus and lacks relevance in Australian context". Equality Australia (Press release). 10 April 2024. Archived from the original on 10 April 2024. Retrieved 11 April 2024.
  125. ↑ Deor, Antimony (14 April 2024). "How Will The Cass Review Affect Aussie Trans Youth?". Star Observer (News). Archived from the original on 24 April 2024. Retrieved 24 April 2024.
  126. ↑ "UK: Cass review on gender identity is being 'weaponised' by anti-trans groups". Amnesty International (Press release). 10 April 2024. Archived from the original on 12 April 2024. Retrieved 11 April 2024.
  127. ↑ Alfonseca, Kiara (11 April 2024). "What the trans care recommendations from the NHS England report mean". ABC News (News). Archived from the original on 23 April 2024. Retrieved 24 April 2024.
  128. ↑ "The Cass Review damns England's youth-gender services". The Economist (News). 10 April 2024. Archived from the original on 16 April 2024. Retrieved 17 April 2024.
  129. ↑ "Statement on the final report of the Cass Review" (Press release). Equality and Human Rights Commission. Archived from the original on 17 April 2024. Retrieved 17 April 2024.
  130. ↑ Bell, David (26 April 2024). "The Cass review of gender identity services marks a return to reason and evidence – it must be defended". The Guardian. ISSN   0261-3077. Archived from the original on 3 July 2024. Retrieved 29 April 2024.
  131. ↑ Vinter, Robyn (11 April 2024). "Trans children in England worse off now than four years ago, says psychologist". The Guardian. ISSN   0261-3077. Archived from the original on 3 July 2024. Retrieved 14 April 2024.
  132. ↑ "Contentious UK gender medicine report prompts reflection, outrage in Australia". Sydney Morning Herald. Archived from the original on 12 April 2024. Retrieved 11 April 2024.
  133. ↑ "NZ Government won't say if it will follow UK's move to ban routine use of puberty blockers as treatment for trans youth". The New Zealand Herald . 10 April 2024. Archived from the original on 19 April 2024. Retrieved 19 April 2024.
  134. ↑ Crimmins, Tricia (10 April 2024). "JK Rowling, gender critical U.K. groups cheer release of Cass Review—as activists push back". The Daily Dot. Archived from the original on 22 April 2024. Retrieved 17 April 2024.
  135. ↑ "The breakdown of JK Rowling and the Harry Potter cast's relationship". The Independent. 12 April 2024. Archived from the original on 22 April 2024. Retrieved 22 April 2024.
  136. ↑ McLaughlin, Charlotte (11 April 2024). "JK Rowling 'won't forgive' Daniel Radcliffe and Emma Watson over trans rights row". Evening Standard. Archived from the original on 22 April 2024. Retrieved 22 April 2024.
  137. ↑ Alsalem, Reem (24 April 2024). "Implementation of 'Cass report' key to protecting girls from serious harm, says UN Special Rapporteur on violence against women and girls, Reem Alsalem". United Nations: Human Rights Council - Office of the High Commissioner. Archived from the original on 28 April 2024. Retrieved 28 April 2024.
  138. 1 2 Hunter, Ross (2 July 2024). "Cass Review contains 'serious flaws', according to Yale Law School". The National. Archived from the original on 2 July 2024. Retrieved 3 July 2024.
  139. 1 2 Alfonseca, Kiara (9 July 2024). "New report critiques UK transgender youth care research study". ABC News. Archived from the original on 11 July 2024. Retrieved 13 July 2024.
  140. ↑ "White Paper Addresses Key Issues in Legal Battles over Gender-Affirming Health Care | Yale Law School". law.yale.edu. 1 July 2024. Archived from the original on 9 August 2024. Retrieved 9 August 2024.
  141. 1 2 Beal, James (19 April 2024). "Hilary Cass: I can't travel on public transport after gender report". The Times. Archived from the original on 20 April 2024. Retrieved 20 April 2024.
  142. ↑ Gecsoyler, Sammy (20 April 2024). "Hilary Cass warned of threats to safety after 'vile' abuse over NHS gender services review". The Guardian . Archived from the original on 21 April 2024. Retrieved 23 April 2024.
  143. 1 2 Beal, James (23 April 2024). "Cass author condemns 'misinformation' spread by trans lawyer". The Times . Archived from the original on 22 April 2024. Retrieved 23 April 2024.
  144. ↑ Vickers-Price, Rachel (20 April 2024). "Hilary Cass says criticism of gender care review 'inaccurate' and 'unforgivable'". The Independent . Archived from the original on 28 April 2024. Retrieved 28 April 2024.
  145. ↑ "Hilary Cass says criticism of gender care review 'inaccurate' and 'unforgivable'". ITV News . 20 April 2024. Archived from the original on 20 April 2024. Retrieved 23 April 2024.
  146. ↑ "Cass Review: Gender report author cannot travel on public transport over safety fears". Sky News . 20 April 2024. Archived from the original on 23 April 2024. Retrieved 23 April 2024.
  147. ↑ Hansford, Amelia (24 April 2024). "Labour MP says she 'inadvertently misled' parliament on Cass report". PinkNews. Archived from the original on 24 April 2024. Retrieved 25 April 2024.
  148. ↑ "Points of Order: Volume 748: debated on Monday 22 April 2024". Hansard. 22 April 2024. Archived from the original on 24 April 2024. Retrieved 24 April 2024.
  149. ↑ "It's misleading to say 100 studies were not included in the Cass Review". Full Fact. 20 May 2024. Archived from the original on 22 May 2024. Retrieved 22 May 2024.
  150. ↑ "Hilary Cass Says U.S. Doctors Are 'Out of Date' on Youth Gender Medicine". The New York Times. 13 May 2024. Archived from the original on 13 May 2024. Retrieved 13 May 2024.
  151. ↑ "'The evidence was disappointingly poor': The full interview with Dr. Hilary Cass". www.wbur.org. WBUR-FM. 8 May 2024. Archived from the original on 16 May 2024. Retrieved 19 May 2024.

Works cited

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.